Fluor Daniel to process radioisotopes

Article

The Canadian subsidiary of engineering and construction firm Fluor Daniel of Irvine, CA, has won a contract to process medical radioisotopes produced by the Maple reactor complex being built by Atomic Energy of Canada (AECL). Fluor Daniel Canada will

The Canadian subsidiary of engineering and construction firm Fluor Daniel of Irvine, CA, has won a contract to process medical radioisotopes produced by the Maple reactor complex being built by Atomic Energy of Canada (AECL). Fluor Daniel Canada will construct a processing facility near the Maple complex to house hot cells, which are used for the separation of isotopes.

AECL is building the Maple reactors to provide a stable supply of radioisotopes such as molybdenum, the raw material for technetium-99m, a commonly used radioisotope in nuclear medicine studies. The age of the existing AECL reactor that is being used to produce molybdenum has concerned nuclear medicine physicians, and a labor dispute at AECL caused a brief shutdown of molybdenum shipments last summer (SCAN 7/9/97). The Maple reactors are scheduled to be completed by 1999, with medical isotope production beginning some time after that.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.